

Supplementary information

Table 1 – OSTRICH Phase 1 Questionnaire

Questions	Possible answers
Does this patient have non-infectious uveitis/ non-infectious scleritis?	<ul style="list-style-type: none"> - Yes - No
Has this patient been under follow-up for at least 6 months?	<ul style="list-style-type: none"> - Yes - No
Patient's current age in years	<ul style="list-style-type: none"> - Free text
Has this patient had active uveitis/scleritis in the last year?	<ul style="list-style-type: none"> - Yes - No
Diagnosis	<ul style="list-style-type: none"> - Non-infectious chronic anterior uveitis - Non-infectious intermediate uveitis - Non-infectious panuveitis - Non-infectious posterior uveitis - Non-infectious scleritis
Are there any sight-threatening features at this present consultation?	<ul style="list-style-type: none"> - Macular oedema - Retinal vasculitis at the macula - Retinal vasculitis at the periphery - Vitritis - Other - ... Please specify - None
When was the diagnosis of non-infectious uveitis made?	<ul style="list-style-type: none"> - < 12 months ago - 1 year - 3 years ago - > 3 years ago
Does this patient have associated systemic disease?	<ul style="list-style-type: none"> - Yes - ... Please specify - No
Is the inflammation controlled or uncontrolled at this present consultation?	<ul style="list-style-type: none"> - Controlled - Uncontrolled
Has the patient been maintained on >7.5mg prednisolone consecutively for more than 3 months within the last 12 months?	<ul style="list-style-type: none"> - Yes - ... What was the maximum dose of prednisolone during that time? - ... Free text - ... Was this patient maintained on >7.5mg prednisolone for systemic disease rather than for ocular inflammation? - ... Yes - ... No - No
If your patient has been on a course of high dose steroid in the last 12 months, did they reduce to < 7.5mg/day within 3 months of starting the course of steroids without recurrence of active disease?	<ul style="list-style-type: none"> - Yes - No - N/A did not receive a high dose course
Is this patient on bone protection?	<ul style="list-style-type: none"> - Yes, on calcium - Yes, on a bisphosphonate - Yes, on calcium and a bisphosphonate - No, not on any bone protection - I don't know

How many courses of ≥ 40 mg oral OR 500mg i.v pulse of steroid have they received in the last 12 months?	<ul style="list-style-type: none"> - 0 - 1 - 2 - 3 - >3 - I don't know - Other - ... Please specify
What is the patient's current treatment at the time of your consultation?	<ul style="list-style-type: none"> - On no treatment - Prednisolone - ... Please specify total dose in mg/day - Ozurdex within the last 6 months - Iluvien within the last 6 months - Periocular steroid within the last 3 months - Intravitreal triamcinolone within the last 3 months - Steroid drops - Azathioprine - ... Please specify total dose in mg/day - Mycophenolate mofetil - ... Please specify total dose in g/day - Tacrolimus - ... Please specify total dose in mg/day - Methotrexate - ... Please specify total dose in mg/week - Ciclosporin - ... Please specify total dose in mg/day - Adalimumab 40mg/fortnight - Infliximab - Interferon alpha 2a - Other - ... please specify
What other treatment(s) has the patient been on in the last 12 months?	<ul style="list-style-type: none"> - On no treatment - Prednisolone - ... Please specify maximum dose in mg/day - Ozurdex within the last 6 months - Iluvien within the last 6 months - Periocular steroid within the last 3 months - Intravitreal triamcinolone within the last 3 months - Steroid drops - Azathioprine - ... Please specify maximum dose in mg/day - Mycophenolate mofetil - ... Please specify maximum dose in g/day - Tacrolimus - ... Please specify maximum dose in mg/day - Methotrexate - ... Please specify maximum dose in mg/week - Ciclosporin - ... Please specify maximum dose in mg/day - Adalimumab 40mg/fortnight - Infliximab - Interferon alpha 2a - Other - ... please specify

Table 2 – treatments received in the last 12 months

Treatments received in the pst 12 months	Number of patients (% of 667 eligible patients)
None	43 (6.4%)
Prednisolone any dose	285 (42.7%)
CS above threshold*	96 (14.4%)
1. Prednisolone >7.5mg for >3 months	73 (10.9%)
2. >1 course of high dose systemic CS	12 (1.8%)
3. Both 1 and 2	11 (1.6%)
Ozurdex within the last 6 months	33 (4.9%)
Iluvien within the last 6 months	2 (0.3%)
Peri-ocular corticosteroid within the last 6 months	35 (5.2%)
Intravitreal triamcinolone within the last 6 months	8 (1.2%)
Corticosteroid drops	362 (54.3%)
Azathioprine	37 (5.5%)
Mycophenolate	138 (20.7%)
Tacrolimus	19 (2.8%)
Methotrexate	80 (12.0%)
Ciclosporin	7 (1.0%)
Adalimumab	60 (9.0%)
Infliximab	22 (3.3%)
Interferon alpha 2a	0 (0%)
Other	92 (13.8%)
* Excess maintenance corticosteroid (CS) or excess high dose systemic CS. 9 patients on CS for systemic disease were excluded	

Table 3 – proportion of patients having received a biologic and IMT in patients treated with CS below vs above threshold

	Patients treated with CS below threshold	Patients treated with CS above threshold	95% CI (p-value)
Proportion (number) of patients treated with a biologic	10% (21)	16% (15)	-14 to 4 (0.239)
Proportion (number) of patients treated with IMT	47%(88)	69% (66)	-0.35 to -0.10 (0.00061) *
* Indicates statistical significance			

Table 4 – median dose of IMT for patients treated with CS below and above threshold

		Median dose of IMT for patients treated with CS below threshold	Median Dose of IMT for patients treated with CS above threshold	95% CI (p-value)
Azathioprine mg/day (IQR)	Current	150 (50)	125 (56.25)	-50 to 50 (0.982)
	Maximum in past year	150 (50)	150 (50)	-50 to 50 (1)
Mycophenolate g/day (IQR)	Current	2 (0)	2 (0)	-3.0 to 2.6 (0.413)
	Maximum in past year	2 (0)	2 (0)	-5.8 to 1.1 (0.552)
Tacrolimus mg/day (IQR)	Current	2.5 (1.75)	3 (1.5)	-2.0 to 2.0 (0.870)
	Maximum in past year	3 (1.5)	3 (1.5)	-2.5 to 1.0 (0.553)
Methotrexate mg/week (IQR)	Current	15 (5)	17.5 (5)	-2.5 to 5.0 (0.715)
	Maximum in past year	15 (6.25)	20 (5)	-5.0 to 6.4 (0.08)
Cyclosporin mg/day (IQR)	Current	100 (50)	200 (0)	NA
	Maximum in past year	125 (62.5)	200 (0)	NA